A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerAlberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|British Journal of Cancer|2012Cited by 51
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).Richard R. Furman, Langdon L. Miller, Jacqueline C. Barrientos et al.|Journal of Clinical Oncology|2012Cited by 24
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, John P. Leonard, Nina D. Wagner‐Johnston et al.|Blood Advances|2016Cited by 19
A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).Corey J. Langer, M. S. Berger, István Albert et al.|Journal of Clinical Oncology|2011Cited by 19
A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.Ian W. Flinn, Albert S. Yu, Marshall T. Schreeder et al.|Journal of Clinical Oncology|2011Cited by 18